{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:07:49Z","timestamp":1789175269818,"version":"build-2803163510"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Progressive Supranukle\u00e4re Blickparese (PSP) und die Kortikobasale\n                    Degeneration (Corticobasal Degeneration, CBD) z\u00e4hlen zu den prim\u00e4ren\n                    Tauopathien, die neuropathologisch durch Ablagerungen von 4-Repeat-Tau-Proteinen\n                    charakterisiert sind. Beide Erkrankungen f\u00fchren zu einer progredienten\n                    Beeintr\u00e4chtigung von Motorik, Gleichgewicht, Sprache, Kognition und\n                    Alltagsfunktion. W\u00e4hrend die PSP h\u00e4ufig mit einer axial betonten Symptomatik und\n                    einer charakteristischen Mittelhirnatrophie einhergeht, zeigt sich bei der CBD\n                    meist eine asymmetrische frontoparietale Atrophie mit kortikalen und\n                    subkortikalen Defiziten. Aufgrund \u00fcberlappender klinischer Ph\u00e4notypen gestaltet\n                    sich die Abgrenzung beider Erkrankungen von anderen neurodegenerativen\n                    Erkrankungen im klinischen Alltag oftmals schwierig. Dabei ist zwischen der\n                    neuropathologisch definierten CBD und dem klinischen Ph\u00e4notyp des kortikobasalen\n                    Syndroms (Corticobasal Syndrome, CBS) zu unterscheiden, welches auch durch\n                    andere Pathologien, etwa eine Alzheimer-Pathologie verursacht sein kann. Die\n                    Diagnose einer PSP oder CBD erfolgt gem\u00e4\u00df den aktuellen klinischen Kriterien und\n                    basiert auf der Beurteilung mehrerer funktioneller Dom\u00e4nen entsprechend der\n                    Auspr\u00e4gung der Symptome. Eine krankheitsmodifizierende Therapie steht bislang\n                    nicht zur Verf\u00fcgung. Die Behandlung verfolgt derzeit symptomorientierte Ans\u00e4tze\n                    mit dem Ziel, Lebensqualit\u00e4t und Selbstst\u00e4ndigkeit der betroffenen Personen\n                    m\u00f6glichst lange zu erhalten.Dieser Artikel bietet einen aktuellen \u00dcberblick \u00fcber\n                    die Diagnose, den Behandlungsansatz, die klinischen Erscheinungsbilder sowie die\n                    Behandlungsm\u00f6glichkeiten f\u00fcr betroffene Personen mit PSP und CBD.<\/jats:p>","DOI":"10.1055\/a-2895-4480","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:34:31Z","timestamp":1789173271000},"page":"389-399","source":"Crossref","is-referenced-by-count":0,"title":["4-Repeat Tauopathien \u2013 Progressive Supranukle\u00e4re Blickparese und\n                    kortikobasale Degeneration"],"prefix":"10.1055","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-8145","authenticated-orcid":false,"given":"Carla Teresa","family":"Palleis","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["LMU Klinikum, Neurologische Klinik und Poliklinik"]},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen\n                    Standort M\u00fcnchen, Germany","place":["M\u00fcnchen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["LMU Klinikum, Neurologische Klinik und Poliklinik"]},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen\n                    Standort M\u00fcnchen, Germany","place":["M\u00fcnchen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["LMU Klinikum, Neurologische Klinik und Poliklinik"]},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen\n                    Standort M\u00fcnchen, Germany","place":["M\u00fcnchen"]},{"name":"Munich Cluster for Systems Neurology (Synergy), Germany","place":["M\u00fcnchen"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12208","article-title":"Invited review: Neuropathology of tauopathies: principles and practice","volume":"41","author":"G G Kovacs","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder\n                    society criteria","volume":"32","author":"G U H\u00f6glinger","year":"2017","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"M J Armstrong","year":"2013","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: A retrospective\n                    multicenter study of 100 definite cases","volume":"29","author":"G Respondek","year":"2014","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","article-title":"Four-repeat tauopathies","volume":"180","author":"T W R\u00f6sler","year":"2019","journal-title":"Prog Neurobiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"G G Kovacs","year":"2020","journal-title":"Acta Neuropathol (Berl)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1038\/s41467-024-52025-x","article-title":"Genetic, transcriptomic, histological, and biochemical analysis of progressive\n                    supranuclear palsy implicates glial activation and novel risk genes","volume":"15","author":"K Farrell","year":"2024","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.859","article-title":"Identification of common variants influencing risk of the tauopathy progressive\n                    supranuclear palsy","volume":"43","author":"G U H\u00f6glinger","year":"2011","journal-title":"Nat Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.27034","article-title":"Which ante-mortem clinical features predict progressive supranuclear palsy\n                    pathology?","volume":"32","author":"G Respondek","year":"2017","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/archneur.1968.00470310034003","article-title":"Corticodentatonigral degeneration with neuronal achromasia","volume":"18","author":"J J Rebeiz","year":"1968","journal-title":"Arch Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"H Ling","year":"2010","journal-title":"Brain J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","article-title":"Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior\n                    disorder with or without a coexisting neurologic disorder","volume":"14","author":"B F Boeve","year":"2013","journal-title":"Sleep Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","article-title":"How to apply the movement disorder society criteria for diagnosis of progressive\n                    supranuclear palsy","volume":"34","author":"M-J Grimm","year":"2019","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/mds.28263","article-title":"Clinical Conditions \u201cSuggestive of Progressive Supranuclear Palsy\u201d\u2014Diagnostic\n                    Performance","volume":"35","author":"M-J Grimm","year":"2020","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"L I Golbe","year":"2007","journal-title":"Brain J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1212\/01.wnl.0000223826.84080.97","article-title":"Measuring quality of life in PSP: the PSP-QoL","volume":"67","author":"A Schrag","year":"2006","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mds.27964","article-title":"The Progressive Supranuclear Palsy Clinical Deficits Scale","volume":"35","author":"I Piot","year":"2020","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s\n                    Association Workgroup","volume":"20","author":"C R Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1212\/cont.0000000000001607","article-title":"Progressive Supranuclear Palsy and Corticobasal Syndrome","volume":"31","author":"N R McFarland","year":"2025","journal-title":"Contin Minneap Minn"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.694872","article-title":"Best Practices in the Clinical Management of Progressive Supranuclear Palsy and\n                    Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care","volume":"12","author":"B Bluett","year":"2021","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"606925","DOI":"10.3389\/fneur.2020.606925","article-title":"Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc\n                    Analysis of the Davunetide Trial","volume":"11","author":"M L Dale","year":"2020","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11940-018-0488-3","article-title":"Botulinum Toxin Treatment of Movement Disorders","volume":"20","author":"Y Safarpour","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1212\/WNL.57.3.467","article-title":"Randomized placebo-controlled trial of donepezil in patients with progressive\n                    supranuclear palsy","volume":"57","author":"I Litvan","year":"2001","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jamaneurol.2023.5215","article-title":"Concomitant Medications for Progressive Supranuclear Palsy: A Secondary Analysis\n                    of a Randomized Clinical Trial","volume":"81","author":"J M Iyer","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"371.e11","DOI":"10.1016\/j.jamda.2017.12.098","article-title":"Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II.\n                    Psychotropics","volume":"19","author":"L J Seppala","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","article-title":"CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled,\n                    double-blind trial","volume":"3","author":"D Apetauerova","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A\n                    randomized, placebo-controlled trial","volume":"23","author":"M Stamelou","year":"2008","journal-title":"Mov Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14802\/jmd.20173","article-title":"Environmental Risk Factors for Progressive Supranuclear Palsy","volume":"14","author":"H K Park","year":"2021","journal-title":"J Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70078","DOI":"10.1002\/alz.70078","article-title":"Insights into pathophysiology, biomarkers, and therapeutics in tauopathies:\n                    Proceedings of the Tau2024 Global Conference","volume":"21","author":"B Frost","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207901","article-title":"Association of Neurofilament Light Chain, [18F]PI-2620 Tau-PET, TSPO-PET, and\n                    Clinical Progression in Patients With \u03b2-Amyloid-Negative CBS","volume":"102","author":"C Palleis","year":"2024","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian\n                    disorder","volume":"88","author":"O Hansson","year":"2017","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2024.3162","article-title":"Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear\n                    Palsy","volume":"81","author":"I Martinez-Valbuena","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/mds.29866","article-title":"Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive\n                    Supranuclear Palsy in Clinical Trials","volume":"39","author":"A Quattrone","year":"2024","journal-title":"Mov Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy","volume":"77","author":"M Brendel","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/mds.28395","article-title":"In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies","volume":"36","author":"C Palleis","year":"2021","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.28470","article-title":"A Modified Progressive Supranuclear Palsy Rating Scale","volume":"36","author":"M-T Gr\u00f6tsch","year":"2021","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/mds.29936","article-title":"A Short Progressive Supranuclear Palsy Quality of Life Scale","volume":"39","author":"I Wilkens","year":"2024","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"644064","DOI":"10.3389\/fneur.2021.644064","article-title":"DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective\n                    Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With\n                    Progressive Supranuclear Palsy","volume":"12","author":"G Respondek","year":"2021","journal-title":"Front Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat\n                    tauopathies","volume":"17","author":"M Stamelou","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4103\/NRR.NRR-D-23-02057","article-title":"Antisense oligonucleotides provide optimism to the therapeutic landscape for\n                    tauopathies","volume":"20","author":"G A Harris","year":"2024","journal-title":"Neural Regen Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14283\/jpad.2018.45","article-title":"AADvac1, an Active Immunotherapy for Alzheimer\u2019s Disease and Non Alzheimer\n                    Tauopathies: An Overview of Preclinical and Clinical Development","volume":"6","author":"P Novak","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70104","article-title":"Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA\n                    Inhibitor ASN90 in Healthy Participants","author":"R Pokorny","year":"2025","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70049","article-title":"AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter,\n                    Randomized Trial, and Open-Label Extension on Safety, Biomarkers, and Disease\n                    Progression","author":"J-C Corvol","year":"2025","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12419-9","article-title":"Low-intensity vestibular noise stimulation improves postural symptoms in\n                    progressive supranuclear palsy","author":"M Wuehr","year":"2024","journal-title":"J Neurol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1055\/a-2823-2465","article-title":"Molekulare Bildgebung von Tau- und \u03b1-Synuclein-Pathologien: technische\n                    Fortschritte, Herausforderungen und Potenziale","author":"JS Gn\u00f6rich","journal-title":"Fortschr Neurol Psychiatr"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2895-4480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:34:45Z","timestamp":1789173285000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2895-4480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2895-4480","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}